P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy

• A. Bardia,
• L. Pusztai,
• K. Albain,
• K. Kalinsky,
• D. Hershman,
• W. Barlow,
• E. Tokunaga,
• E.M. Ciruelos,
• D. Loirat,
• C. Isaacs,
• L. Testa,
• H. Dry,
• R. Kozarski,
• M. Maxwell,
• N. Harbeck,
• P. Sharma

Affiliations

A. Bardia

L. Pusztai

K. Albain

K. Kalinsky

D. Hershman

W. Barlow

E. Tokunaga

E.M. Ciruelos

D. Loirat

C. Isaacs

L. Testa

H. Dry

R. Kozarski

M. Maxwell

N. Harbeck

P. Sharma